When things go wrong at the speculative end of any sector, they go very wrong. Take the recently booming biotechs where the challenge for investors is the outcome is so often binary.
When things go wrong at the speculative end of any sector, they go very wrong.
Take the recently booming biotech sector. The challenge for investors is the outcome is so often binary, and usually revolves around the regulatory approval or otherwise of a new drug or device.
